T-DXd plus pertuzumab was approved in China as first-line treatment for unresectable or metastatic HER2-positive breast cancer.
News|Articles|January 28, 2026
Ultrasensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
Author(s)Jax DiEugenio
Fact checked by: Chris Ryan, Ron Panarotti
The emergence of ultrasensitive ctDNA and CSF testing may help alter monitoring strategies and adaptive clinical trial designs in metastatic breast cancer.
Advertisement
Advertisement
Ultrasensitive circulating tumor DNA (ctDNA) monitoring is increasingly reframing how metastatic breast cancer clinical trials are designed and how treatment decisions may be timed, shifting the focus from reacting to radiographic progression to intervening at the earliest molecular signs of resistance.1
Related to this article
Breast cancer experts share insights on how recently approved indications for 3 ADCs will affect clinical practice.
Sara Nunnery, MD, MSCI, and Kelly E. McCann, MD, PhD, discuss practice-changing data with T-DXd for HER2-positive breast cancer.
Komal Jhaveri, MD, FACP, discusses the role of CDK4/6 inhibitors for patients with hormone receptor–positive disease and how oral SERD use is changing.
A surgical team from Huntsman Cancer Institute at the University of Utah has performed the first robotic mastectomy in the Mountain West.
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The top 5 OncLive TV videos of the week cover insights in melanoma, prostate cancer, breast cancer, multiple myeloma, and small cell lung cancer.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Advertisement
Advertisement